Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Factors Associated with Delayed Clinical Evaluation for Patients with Intracerebral Hemorrhage in the ERICH Study
Cerebrovascular Disease and Interventional Neurology
S41 - Sociodemographics of Stroke and Policy in Stroke Care (2:48 PM-3:00 PM)
010

ICH is one of the deadliest stroke types. Current guidelines on acute ICH management rely on ischemic stroke literature to determine factors associated with delayed presentation in ICH. Earlier imaging is critical to diagnosis and treatment.

To evaluate patient-level factors independently associated with shorter Onset-to-CT (OCT) times among patients with Intracerebral Hemorrhage (ICH).  

Data from patients enrolled in ERICH, one of the largest multicenter, prospective, case-controlled observational ICH studies, were evaluated. Patients with missing/inaccurate onset and initial CT times, missing/in-hospital onset location, OCT >24 hours, GCS 3, and pre-morbid mRS >3 were excluded. Patients were categorized as having received CT within 1 hour vs greater than 1 hour after onset. Pearson X2 and Mann-Whitney U tests were performed for categorical and continuous variables, respectively. A binary logistic regression was performed to evaluate factors associated with receiving CT within 1 hour. Adjusted odds ratios with 95% confidence intervals are reported. All p-values were 2-sided, and significance was defined as a p-value <0.05.

Across the two epochs (n=978), median age was 60 (IQR: 51-72), 39.5% were female, and median OCT time was 2 hours (IQR: 1-3). 38.4% (n=376) received CT within 1 hour of LKW vs 61.6% (n=602) who received CT after 1 hour. After adjusting for age, ethnicity, stroke severity, bleed location, systolic BP, EMS arrival, and location of onset, the factors associated with decreased OCT time were arrival by EMS (OR, 3.24, 95% CI, 2.18-4.80), identifying as Hispanic (OR, 1.56, 95% CI, 1.17-2.08), non-lobar bleeds (OR, 1.51, 95% CI,1.07-2.13). Patients with decreased severity (higher GCS), were more likely to have prolonged OCT times (OR, 0.94, 95% CI, 0.90-0.99).

These findings suggest considerable potential for addressing patient-level factors that lead to delayed diagnosis and treatment for ICH.

Authors/Disclosures
Dheeraj D. Lalwani (Yale University School of Medicine, Department of Neurology)
PRESENTER
Mr. Lalwani has nothing to disclose.
Julia Zabinska Ms. Zabinska has nothing to disclose.
Emma S. Peasley (Yale School of Medicine) Miss Peasley has nothing to disclose.
Adam De Havenon, MD, FAAN (Yale University) Dr. De Havenon has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Novo Nordisk. Dr. De Havenon has stock in Certus. Dr. De Havenon has stock in TitinKM. The institution of Dr. De Havenon has received research support from NIH/NINDS. Dr. De Havenon has received publishing royalties from a publication relating to health care.
Guido J. Falcone, MD (Yale School of Medicine) The institution of Dr. Falcone has received research support from NIH. The institution of Dr. Falcone has received research support from AHA.
Joshua Goldstein (Massachusetts General Hospital) Joshua Goldstein has received personal compensation in the range of $500-$4,999 for serving as a Consultant for CSL Behring. Joshua Goldstein has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Portola. Joshua Goldstein has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Ncontrol. The institution of Joshua Goldstein has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Octapharma. Joshua Goldstein has received stock or an ownership interest from NControl. The institution of Joshua Goldstein has received research support from Pfizer. The institution of Joshua Goldstein has received research support from Takeda.
Daniel Woo, MD, FAAN (University of Cincinnati) Dr. Woo has nothing to disclose.
Kevin N. Sheth, MD, FAAN (Yale UniversityDivision of Neuro and Critical Care) Dr. Sheth has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Ceribell. Dr. Sheth has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Zoll. Dr. Sheth has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for NControl. Dr. Sheth has received stock or an ownership interest from Astrocyte. Dr. Sheth has received stock or an ownership interest from Alva. The institution of Dr. Sheth has received research support from Biogen. The institution of Dr. Sheth has received research support from Novartis. The institution of Dr. Sheth has received research support from Bard. The institution of Dr. Sheth has received research support from Hyperfine. Dr. Sheth has received intellectual property interests from a discovery or technology relating to health care.